Oncogenic gene fusions involving the neurotrophic tyrosine receptor kinase (NTRK) occur in numerous adult and paediatric tumour types [1-4], and have thus emerged as a promising therapeutic target across several tumour histologies . The estimated frequency of NTRK gene fusions varies between tumour types ranging from a prevalence of >90% in some rare cancers (secretory carcinoma of the breast and salivary glands and infantile fibrosarcoma) to <1% in more common cancer types (click here to learn more about the epidemiology of NTRK gene fusions) [1-3]. The protein product of NTRK gene fusions (referred to as a tropomyosin receptor kinase [TRK] fusion protein) is constitutively active and results in cell growth, proliferation and survival pathway activation [1, 3, 4].
- Amatu A, Sartore-Bianchi A, Siena S. NTRK gene fusions as novel targets of cancer therapy across multiple tumour types. ESMO Open 2016; 1: e000023.
- Stransky N, Cerami E, Schalm S et al. The landscape of kinase fusions in cancer. Nat Commun 2014; 5: 4846.
- Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol 2018; 15: 731-747.
- Vaishnavi A, Le AT, Doebele RC. TRKing down an old oncogene in a new era of targeted therapy. Cancer Discov 2015; 5: 25-34.